Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Gain Therapeutics, Inc.

NASDAQ: GANX · Life Sciences · 5 alerts · CIK 1819411

Share price
$0.9402Close, Nov 16
Market cap
$41.9M
Shares outstanding
44.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Gain Therapeutics, Inc. filings on SEC EDGAR ↗

9:16 AM ET 8-K
Clinical Trial Data

Gain Therapeutics Clinical Trial Data

Gain Therapeutics presented 12-month open-label extension data from its Phase 1b study of rexaceract, showing stabilization of MDS-UPDRS motor scores in Parkinson’s disease patients. The data suggests disease-modifying potential as patients showed no clinically meaningful progression of motor symptoms over the one-year period. The company plans to submit a Phase 2 protocol to the FDA and initiate a Phase 2 trial in Q1 2027.

Term
12 months

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.